Orphan designation: posnafusp alfa Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome), 14/01/2022 Positive
Orphan designation: posnafusp alfa Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome), 14/01/2022 Positive
Orphan designation: posnafusp alfa Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome), 14/01/2022 Positive
Orphan designation: autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human claudin 18.2 antigen with CD28 and CD3-zeta intracellular signalling domains Treatment of gastric cancer, 19/02/2021 Positive
Orphan designation: small-interfering RNA against soluble fms-like tyrosine kinase-1 e15a mRNA, small-interfering RNA against soluble fms-like tyrosine kinase-1 i13 mRNA Treatment of pre-eclampsia, 16/04/2025 Positive
Orphan designation: humanised IgG1 monoclonal antibody against muscle specific kinase Treatment of spinal muscular atrophy, 16/04/2025 Positive
Orphan designation: vamikibart Treatment of non-infectious uveitis, 16/04/2025 Positive
PSUSA/00000051/202410
EMA closed 9 June
QRD veterinary product-information highlighted template version 9.1
QRD veterinary product-information template version 9.1
QRD veterinary combined label-leaflet template v.9.1